A new treatment option for chronic hepatitis B infection improves the chance of cure hepatitis B. With the help of short pieces of RNA, it is a collaboration of the Helmholtz Center Munich, Technical University of Munich and the University of Bonn succeeded in the reproduction of the hepatitis B virus and to stop at the same time to stimulate the immune system. The study is published in the prestigious journal Gastroenterology.
The team led by Prof. Ulrike Protzer, director of the Institute for Virology, Helmholtz Center Munich and the Technical University of Munich, in collaboration with Dr. Hendrik Poeck, the right of the Isar Hospital in Munich Technical University, and Professor Gunther Hartmann of the University of Bonn a new treatment option for chronic hepatitis B develops. The study published in Gastroenterology describes the use of siRNAs * that have been specifically modified. The designers RNA fragments inhibit the replication of the hepatitis B virus in the body, but still have another function. They stimulate the immune system, thus again can effectiveness in combating the virus , "Our study shows that the combination of both functions - the inhibition of virus replication and immune stimulation - in a siRNA is significantly more effective than the corresponding mono-functional nucleic acids, "says Prof. Ulrike Protzer, director of the study. "We have used this approach for the first time the prospect of the hepatitis B virus infection even with a chronic low back completely remove from the body." If chronic hepatitis B, although they can develop drugs through controlled but not cured. The infection is approximately 350 million cases worldwide one of the most important viral diseases of humans and can be seen by the high number of cases as a public health problem. The understanding of the pathophysiology of common diseases and the derivation of new targets for diagnosis, therapy and prevention is the goal of the Helmholtz Zentrum München.
In Germany the news about "the new treatment" made it into the big newspapers. Yet I could not find out if they have already started clinical studies. Basically it says that they stopped the virus from replication AND modulated the immune system in a way that reinfection of cells got stopped.
After Myrcludex-B and REP9AC this seems to be a third new reason for hope to get rid of pesty HepB.....Since I am German I might write them an email on how far the testing of this new drug has proceeded. Did that on Myrcludex B too and got the answer that they are testing it on healthy patients, and next year they scheduled to test in on "us"! So long...keep it up.
please let's keep us updated, germany and holland are the best places for research and the only ones against the US drug makers making useless nucs, i am sure they will develop both drugs
please follow closely Myrcludex B and which universities are or will test on hbv carriers, it is also good that being in euripean community we have free access to healthcare systems (at least italy with other EC) and germany is for sure the best and most advanced on hbv especially hamburg university hospital
I had email contact with Dr. Protzer (University of Munich). She told me that they are testing the new therapy on non-infected persons at the moment. Testing it on "us" is scheduled for 2012. So it's pretty much the same as with Myrcludex B. That`s it for now.
P.S.: I offered to be a test person next year. Once I get some response, I will let you know.....
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.